Prasugrel superior than clopidogrel in the treatment of ACS and STEMI patients undergoing PCI
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Reduced cardiovascular mortality rates were obtained in ACS and STEMI group (p=0.03 and p=0.04, respectively).
Related MIMS Drugs